Nu Skin Enterprises NUS
NYSE · Wholesale-Drugs, Proprietaries & Druggists' Sundries · $243MData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $2.7B | $2.2B | $2.0B | $1.7B | $1.5B | −14.3% | −13.8% | |
| Cost of Revenue (COGS) | $675.2M | $630.9M | $611.9M | $550.2M | $453.8M | −17.5% | −9.5% | |
| Gross Profit | $2.0B | $1.6B | $1.4B | $1.2B | $1.0B | −12.7% | −15.5% | |
| Research & Development (R&D) | $27.2M | $23.3M | $22.6M | $13.0M | $10.8M | −16.9% | −20.6% | |
| Total Operating Expenses | $1.8B | $1.5B | $1.3B | $1.3B | $965.6M | −27.6% | −14.3% | |
| Operating Income (EBIT) | $234.0M | $110.8M | $48.3M | $-151.6M | $65.8M | +143.4% | −27.2% | |
| Interest Expense | $11.0M | $13.5M | $25.6M | $26.4M | $13.9M | −47.2% | +6.1% | |
| Income Tax Expense | $85.2M | $-15.8M | $18.0M | $-28.5M | $36.0M | +226.5% | −19.4% | |
| GAAP Net Income | $147.3M | $104.8M | $8.6M | $-146.6M | $160.2M | +209.3% | +2.1% | |
| Diluted EPS | $2.86 | $2.07 | $0.17 | $-2.95 | $3.18 | +207.8% | +2.7% | |
| Diluted Shares | 51.4M | 50.5M | 49.9M | 49.7M | 50.3M | +1.3% | −0.6% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $339.6M | $264.7M | $256.1M | $186.9M | $238.6M | +27.7% | −8.4% | |
| Inventory | $399.9M | $346.2M | $280.0M | $190.2M | $178.6M | −6.1% | −18.2% | |
| Total Current Assets | $873.0M | $759.9M | $701.9M | $538.6M | $547.7M | +1.7% | −11.0% | |
| Total Assets | $1.9B | $1.8B | $1.8B | $1.5B | $1.4B | −4.3% | −7.3% | |
| Total Current Liabilities | $529.7M | $359.2M | $328.9M | $296.6M | $263.7M | −11.1% | −16.0% | |
| Total Debt (Short + Long Term) | $376.3M | $402.5M | $503.0M | $393.6M | $224.2M | −43.0% | −12.1% | |
| Total Liabilities | $993.7M | $923.7M | $986.7M | $817.5M | $600.1M | −26.6% | −11.8% | |
| Stockholders' Equity | $912.8M | $897.3M | $822.0M | $651.5M | $805.2M | +23.6% | −3.1% | |
| Net Cash / (Net Debt) | $-36.7M | $-137.7M | $-247.0M | $-206.7M | $14.4M | +107.0% | — | |
| Invested Capital | $949.5M | $1.0B | $1.1B | $858.2M | $790.8M | −7.9% | −4.5% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $141.6M | $108.1M | $118.6M | $111.7M | $80.3M | −28.2% | −13.2% | |
| Depreciation & Amortization (D&A) | $76.3M | $72.5M | $70.9M | $69.8M | $52.3M | −25.1% | −9.0% | |
| Stock-Based Compensation (SBC) | $23.2M | $12.4M | $15.6M | $14.8M | $24.1M | +62.6% | +1.0% | |
| Capital Expenditures (CapEx) | $68.6M | $59.1M | $58.5M | $41.6M | $34.3M | −17.6% | −15.9% | |
| Free Cash Flow (FCF) | $73.0M | $49.0M | $60.1M | $70.2M | $46.0M | −34.4% | −10.9% | |
| True FCF (ex-SBC Owner Cash) | $49.8M | $36.6M | $44.5M | $55.3M | $21.9M | −60.4% | −18.6% | |
| Share Repurchases (Buybacks) | $80.4M | $70.0M | $13.0M | $0 | $20.0M | — | −29.3% | |
| Dividends Paid | $76.3M | $77.0M | $77.6M | $11.9M | $11.8M | −0.8% | −37.2% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what NUS did at the next close after each storyNo Wire story has named NUS yet.